The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hospital-Treated Gram-Negative Infections Market Research Report 2025
Synopsis
Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.
The global Hospital-Treated Gram-Negative Infections market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital-Treated Gram-Negative Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Treated Gram-Negative Infections.
Report Scope
The Hospital-Treated Gram-Negative Infections market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital-Treated Gram-Negative Infections market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital-Treated Gram-Negative Infections companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
AstraZeneca
Abbott
Lupin Pharmaceuticals
Istituto lusofarmaco d’italia
Adelco S.A
Zhejiang yuntao biotechnology co., Ltd
Alcon Laboratories
Segment by Type
Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others
Segment by Application
Public Hospital
Private Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hospital-Treated Gram-Negative Infections companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.
The global Hospital-Treated Gram-Negative Infections market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
This report aims to provide a comprehensive presentation of the global market for Hospital-Treated Gram-Negative Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Treated Gram-Negative Infections.
Report Scope
The Hospital-Treated Gram-Negative Infections market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hospital-Treated Gram-Negative Infections market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hospital-Treated Gram-Negative Infections companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Pfizer
AstraZeneca
Abbott
Lupin Pharmaceuticals
Istituto lusofarmaco d’italia
Adelco S.A
Zhejiang yuntao biotechnology co., Ltd
Alcon Laboratories
Segment by Type
Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others
Segment by Application
Public Hospital
Private Hospital
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hospital-Treated Gram-Negative Infections companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hospital-Treated Gram-Negative Infections Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Klebsiella
1.2.3 Acinetobacter
1.2.4 Coli
1.2.5 Cepacia
1.2.6 Pseudomonas
1.2.7 Serratia
1.2.8 Enterobacter
1.2.9 Others
1.3 Market by Application
1.3.1 Global Hospital-Treated Gram-Negative Infections Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Public Hospital
1.3.3 Private Hospital
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hospital-Treated Gram-Negative Infections Market Perspective (2019-2030)
2.2 Hospital-Treated Gram-Negative Infections Growth Trends by Region
2.2.1 Global Hospital-Treated Gram-Negative Infections Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hospital-Treated Gram-Negative Infections Historic Market Size by Region (2019-2024)
2.2.3 Hospital-Treated Gram-Negative Infections Forecasted Market Size by Region (2025-2030)
2.3 Hospital-Treated Gram-Negative Infections Market Dynamics
2.3.1 Hospital-Treated Gram-Negative Infections Industry Trends
2.3.2 Hospital-Treated Gram-Negative Infections Market Drivers
2.3.3 Hospital-Treated Gram-Negative Infections Market Challenges
2.3.4 Hospital-Treated Gram-Negative Infections Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hospital-Treated Gram-Negative Infections Players by Revenue
3.1.1 Global Top Hospital-Treated Gram-Negative Infections Players by Revenue (2019-2024)
3.1.2 Global Hospital-Treated Gram-Negative Infections Revenue Market Share by Players (2019-2024)
3.2 Global Hospital-Treated Gram-Negative Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hospital-Treated Gram-Negative Infections Revenue
3.4 Global Hospital-Treated Gram-Negative Infections Market Concentration Ratio
3.4.1 Global Hospital-Treated Gram-Negative Infections Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hospital-Treated Gram-Negative Infections Revenue in 2023
3.5 Hospital-Treated Gram-Negative Infections Key Players Head office and Area Served
3.6 Key Players Hospital-Treated Gram-Negative Infections Product Solution and Service
3.7 Date of Enter into Hospital-Treated Gram-Negative Infections Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hospital-Treated Gram-Negative Infections Breakdown Data by Type
4.1 Global Hospital-Treated Gram-Negative Infections Historic Market Size by Type (2019-2024)
4.2 Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Type (2025-2030)
5 Hospital-Treated Gram-Negative Infections Breakdown Data by Application
5.1 Global Hospital-Treated Gram-Negative Infections Historic Market Size by Application (2019-2024)
5.2 Global Hospital-Treated Gram-Negative Infections Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hospital-Treated Gram-Negative Infections Market Size (2019-2030)
6.2 North America Hospital-Treated Gram-Negative Infections Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hospital-Treated Gram-Negative Infections Market Size by Country (2019-2024)
6.4 North America Hospital-Treated Gram-Negative Infections Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hospital-Treated Gram-Negative Infections Market Size (2019-2030)
7.2 Europe Hospital-Treated Gram-Negative Infections Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2019-2024)
7.4 Europe Hospital-Treated Gram-Negative Infections Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size (2019-2030)
8.2 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Region (2019-2024)
8.4 Asia-Pacific Hospital-Treated Gram-Negative Infections Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hospital-Treated Gram-Negative Infections Market Size (2019-2030)
9.2 Latin America Hospital-Treated Gram-Negative Infections Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2019-2024)
9.4 Latin America Hospital-Treated Gram-Negative Infections Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size (2019-2030)
10.2 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2019-2024)
10.4 Middle East & Africa Hospital-Treated Gram-Negative Infections Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Hospital-Treated Gram-Negative Infections Introduction
11.1.4 Merck Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Hospital-Treated Gram-Negative Infections Introduction
11.2.4 Pfizer Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Hospital-Treated Gram-Negative Infections Introduction
11.3.4 AstraZeneca Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Abbott
11.4.1 Abbott Company Detail
11.4.2 Abbott Business Overview
11.4.3 Abbott Hospital-Treated Gram-Negative Infections Introduction
11.4.4 Abbott Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.4.5 Abbott Recent Development
11.5 Lupin Pharmaceuticals
11.5.1 Lupin Pharmaceuticals Company Detail
11.5.2 Lupin Pharmaceuticals Business Overview
11.5.3 Lupin Pharmaceuticals Hospital-Treated Gram-Negative Infections Introduction
11.5.4 Lupin Pharmaceuticals Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.5.5 Lupin Pharmaceuticals Recent Development
11.6 Istituto lusofarmaco d’italia
11.6.1 Istituto lusofarmaco d’italia Company Detail
11.6.2 Istituto lusofarmaco d’italia Business Overview
11.6.3 Istituto lusofarmaco d’italia Hospital-Treated Gram-Negative Infections Introduction
11.6.4 Istituto lusofarmaco d’italia Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.6.5 Istituto lusofarmaco d’italia Recent Development
11.7 Adelco S.A
11.7.1 Adelco S.A Company Detail
11.7.2 Adelco S.A Business Overview
11.7.3 Adelco S.A Hospital-Treated Gram-Negative Infections Introduction
11.7.4 Adelco S.A Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.7.5 Adelco S.A Recent Development
11.8 Zhejiang yuntao biotechnology co., Ltd
11.8.1 Zhejiang yuntao biotechnology co., Ltd Company Detail
11.8.2 Zhejiang yuntao biotechnology co., Ltd Business Overview
11.8.3 Zhejiang yuntao biotechnology co., Ltd Hospital-Treated Gram-Negative Infections Introduction
11.8.4 Zhejiang yuntao biotechnology co., Ltd Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.8.5 Zhejiang yuntao biotechnology co., Ltd Recent Development
11.9 Alcon Laboratories
11.9.1 Alcon Laboratories Company Detail
11.9.2 Alcon Laboratories Business Overview
11.9.3 Alcon Laboratories Hospital-Treated Gram-Negative Infections Introduction
11.9.4 Alcon Laboratories Revenue in Hospital-Treated Gram-Negative Infections Business (2019-2024)
11.9.5 Alcon Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
